| Literature DB >> 27683385 |
Emina S Colak1, Nada T Majkic-Singh1, Sanja S Stankovic1, Natalija G Kosanovic-Jakovic2, Lepsa D Zoric2, Aleksandra P Radosavljevic2, Dragana D Terzic1, Jecka Z Stojanovic1.
Abstract
The role of lipid parameters disorder in the development of age-related macular degeneration (AMD) is unclear. The aim of this study was to analyze lipid profile in these patients and to test the influence of gender on lipid profile of AMD patients, especially in the early and late form of the disease. 82 patients with AMD (mean age 70.3 yrs) and 80 age-matched control subjects were included in this study. Serum lipid and apolipoproteiin levels were determined using standardized methods. AMD patients had significantly higher values of total cholesterol (P=0.000), HDL-cholesterol (P=0.0003) and LDL-cholesterol (P=0.000) compared to control group. Significantly higher values of apo A1 (P=0.039), apo E (P=0.002), total-cholesterol (P=0.000), LDL-chol. (P=0.026), total HDL-chol (P=0.000), HDL3-chol. (P=0.005) and non-HDL-cholesterol (P=0.029) were found in female AMD patients compared to males with AMD. Females with the advanced form of the disease had significantly higher total cholesterol (P=0.006), HDL-C (P=0.004), non HDL-C (P=0.05) and apo E (P=0.014) compared to males with the same form of the disease. There is a significant disorder of lipid parameters in AMD patients especially in females. More severe forms of AMD are followed by the increase of atherogenic lipoproteins and apolipoproteins, and females have higher values of these parameters compared to males with the same form of AMD.Entities:
Year: 2011 PMID: 27683385 PMCID: PMC4975327
Source DB: PubMed Journal: EJIFCC ISSN: 1650-3414
Lipid and apolipoprotein parameters in AMD and control subjects
| Parameter | AMD n=82 | CG n=80 | P |
|---|---|---|---|
| Apo A1 (g/L)[ | 1.69 ± 0.36 | 1.62 ± 0.32 | 0.192 |
| Apo A2 (mg/L)[ | 358.1 ± 65.97 | 361.9 ± 65.75 | 0.723 |
| Apo B (g/L)[ | 1.208 ± 0.287 | 1.18 ± 0.255 | 0.514 |
| Apo E (mg/L)[ | 44.5 (38.05-49.05) | 43.9 (36.15-53.87) | 0.852 |
| Lipoprotein (a) (g/L)[ | 0.098 (0.098-0.192) | 0.098 (0.098-0.177) | 0.476 |
| Total cholesterol (mmol/L)[ | 6.25 ± 1.12 | 5.57 ± 0.84 | <0.001 |
| HDL-cholesterol (mmol/L)[ | 1.48 ± 0.33 | 1.43 ± 0.35 | 0.317 |
| LDL-cholesterol (mmol/L)[ | 3.99 ± 1.10 | 3.60 ± 0.91 | 0.018 |
| Triglycerides (mmol/L)[ | 1.56 ± 0.585 | 1.41 ± 0.528 | 0.091 |
| HDL2-cholesterol (mmol/L)[ | 0.379 ± 0.149 | 0.419 ± 0.192 | 0.218 |
| HDL3-cholesterol (mmol/L)[ | 0.883 ± 0.269 | 0.937 ± 0.242 | 0.233 |
| non-HDL-cholesterol (mmol/L)[ | 4.77 ± 1.08 | 4.19 ± 0.82 | <0.001 |
aArithmetic mean ± standard deviation (SD);
bMedian and interquartile
Lipid and apolipoprotein values in subgroups of tested males and females
| Parameter | Males | Females | P | ||
|---|---|---|---|---|---|
| AMD | CG | AMD | CG | ||
| ApoA1 (g/L)[ | 1.57±0.36 | 1.55±0.33 | 1.75±0.35 | 1.71±0.29 | 0.014 |
| ApoA2 (mg/L)[ | 338.4±54.5 | 359.9±66.2 | 365.6±68.8 | 362.0±65.5 | 0.484 |
| ApoB (g/L)[ | 1.13±0.24 | 1.14±0.26 | 1.24±0.30 | 1.22±0.26 | 0.257 |
| Apo E (mg/L)[ | 37.65 | 37.4 | 46.9 | 49.8 | |
| (30.6-44.1) | (36.3-43.1) | (43.2-48.5) | (45.8-54-8) | <0.001 | |
| Lipoprotein (a) (g/L) [ | 0.098 | 0.098 | 0.098 | 0.098 | 0.870 |
| (0.098-0.189) | (0.098-0.101) | (0.098-0.164) | (0.098-0.146) | ||
| Total cholesterol (mmol/L)[ | 5.48±0.95 | 5.41±0.86 | 6.51±1.05 | 5.81±0.75 | <0.001 |
| HDL-cholesterol (mmol/L) | 1.25±0.25 | 1.30±0.29 | 1.56±0.32 | 1.58±0.35 | <0.001 |
| HDL2-cholesterol (mmol/L)[ | 0.32±0.11 | 0.42±0.18 | 0.41±0.16 | 0.41±0.2 | 0.269 |
| HDL-cholesterol (mmol/L)[ | 0.72±0.12 | 0.95±0.23 | 0.95±0.29 | 0.93±0.26 | 0.016 |
| LDL-cholesterol (mmol/L)[ | 3.53±0.84 | 3.45±0.88 | 4.15±1.15 | 3.80±0.93 | 0.003 |
| non-HDL cholesterol (mmol/L)[ | 4.33±0.86 | 4.15±0.81 | 4.92±1.11 | 4.22±0.85 | <0.001 |
| Triglycerides (mmol/L)[ | 1.50±0.70 | 1.32±0.51 | 1.58±0.54 | 1.52±0.54 | 0.155 |
AMD- the patients with age-related macular degeneration; CG- The control group;
a Arithmetic mean ± standard deviation (SD);
b Median and 95% confidence interval for median;
♠ P<0.05, difference between AMD males and females
♢ P<0.05, difference between females and males in the CG
♣ P<0.05, difference between AMD males and males in the CG
Lipid and apolipoprotein values in subgroups of males and females with early and late form of AMD
| Parameter | Males | Females | P | ||
|---|---|---|---|---|---|
| EarlyAMD | Late AMD | EarlyAMD | Late AMD | ||
| ApoA1 (g/L) | 1.33 ± 1.09 | 1.60 ± 0.379 | 1.72 ± 0.337 | 1.75 ± 0.36 | 0.244 |
| ApoA2 (mg/L) | 337.0 ± 29.13 | 341.9 ± 57.49 | 370.37 ± 94.9 | 364.3 ± 61.1 | 0.607 |
| Apo B (g/L) | 0.83 ± 0.05 | 1.18 ± 0.22 | 1.35 ± 0.32 | 1.21 ± 0.29 | 0.097 |
| Apo E (mg/L) | 40.0 ± 2.26 | 38.6 ± 10.7 | 50.87 ± 11.3 | 45.4 ± 8.18 | 0.011 |
| Total cholesterol (mmol/L) | 4.58 ± 0.085 | 5.60 ± 0.966 | 6.72 ± 0.941 | 6.44 ± 1.09 | 0.001 |
| HDL-cholesterol (mmol/L) | 1.18 ± 0.106 | 1.256 ± 0.27 | 1.50 ± 0.311 | 1.58 ± 0.33 | 0.002 |
| HDL2-cholesterol (mmol/L) | 0.535 ± 0.035 | 0.34 ± 0.202 | 0.407 ± 0.126 | 0.399 ± 0.136 | 0.364 |
| HDL3-cholesterol (mmol/L) | 1.21 ± 0.41 | 0.789 ± 0.177 | 0.98 ± 0.253 | 0.911 ± 0.33 | 0.224 |
| LDL-cholesterol (mmol/L) | 2.79 ± 0.11 | 3.63 ± 0.86 | 4.44 ± 1.14 | 4.05 ± 1.15 | 0.071 |
| non-HDL ch (mmol/L) | 5.18 ± 0.93 | 4.28 ± 0.82 | 5.08 ± 1.06 | 4.86 ± 1.14 | 0.125 |
| Triglycerides (mmol/L) | 1.23 ± 0.049 | 1.56 ± 0.73 | 1.78 ± 0.77 | 1.51 ± 0.43 | 0.359 |
• P<0.05, difference between males with early and late form
♡ P<0.05, difference between males and females with early form
♠ P<0.05, difference between females and males with the late form